Alzheimer’s
-
Alzheimer’s & Dementia Care
Alzheimer’s & Brain Awareness Month Mobilizes Global Efforts to Combat Rising Dementia Crisis and Advance Research
June marks Alzheimer’s & Brain Awareness Month, a pivotal period when the Alzheimer’s Association spearheads a comprehensive array of initiatives…
Read More » -
Alzheimer’s & Dementia Care
Study reports Alzheimer’s treatment gains in long-term care
Top-line data emanating from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was linked to significant provider-reported…
Read More » -
Alzheimer’s & Dementia Care
Real-World BEACON Study Highlights Zunveyl’s Potential in Long-Term Alzheimer’s Care with Provider-Reported Improvements.
Top-line data emerging from the BEACON study, a real-world investigation into the therapeutic performance of Zunveyl (benzgalantamine), indicate a positive…
Read More » -
Alzheimer’s & Dementia Care
Zunveyl Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Long-Term Care Study
Top-line data from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was associated with significant provider-reported improvements…
Read More » -
Alzheimer’s & Dementia Care
Zunveyl Demonstrates Positive Provider-Reported Outcomes in Real-World Alzheimer’s Study Among Long-Term Care Patients
Provider observations with Zunveyl cannot prove cause and effect. Top-line data emerging from the BEACON study, a real-world investigation into…
Read More » -
Alzheimer’s & Dementia Care
Real-World Study Illuminates Zunveyl’s Impact on Cognition, Behavior, and Functioning in Long-Term Alzheimer’s Care.
Top-line data from the BEACON real-world study indicate that Zunveyl (benzgalantamine) was associated with significant provider-reported improvements across several critical…
Read More » -
Alzheimer’s & Dementia Care
June happenings aimed at raising funds to get the word out, fuel research
June marks Alzheimer’s & Brain Awareness Month (ABAM), a critical period dedicated to amplifying understanding of Alzheimer’s disease and other…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically targeting…
Read More » -
Alzheimer’s & Dementia Care
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
New analysis presented by Anavex Life Sciences indicates that the therapeutic benefits observed in individuals with early-stage Alzheimer’s disease after…
Read More » -
Alzheimer’s & Dementia Care
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More »
